下一代癌症診斷市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

全球下一代癌症診斷市場到2023 年將達到155 億美元，預計2024 年至2032 年將以10% 的複合年成長率成長。個體遺傳和資料客製化治療方案。先進的診斷技術，包括新一代定序 (NGS) 和液體活體組織切片，對於識別基因突變和特定癌症生物標記至關重要。這些功能增強了早期檢測並最佳化了標靶治療選擇。

下一代癌症診斷引入了先進的工具和技術，能夠實現精確、早期檢測和個人化的癌症分析。這些進步改善了疾病監測和風險評估，從而可以精確選擇標靶治療。透過關注腫瘤獨特的遺傳、分子和細胞特徵，在精準醫療實現更好臨床結果和更有效治療的潛力的推動下，該市場正在引領癌症治療領域的一場革命。

市場分為產品和服務，其中產品細分市場佔據重要佔有率，預計在預測期內將以 9.8% 的複合年成長率成長。該部分包括儀器、套件和消耗品，這些都是診斷準確性和效率所必需的。對廣泛應用於醫院、實驗室和研究機構的先進測序平台、PCR 機器和成像設備的需求很高，對市場收入做出了巨大貢獻。

從技術上講，NGS 領域的下一代癌症診斷市場由於能夠快速、準確地提供詳細的基因組見解，到 2023 年將佔據 32.5% 的佔有率。 NGS 在識別基因突變和生物標記方面的作用對於早期癌症檢測和個人化治療至關重要，隨著癌症盛行率的不斷上升、NGS 的創新和成本的降低推動了採用。

在美國，到 2032 年，下一代癌症診斷市場將以 9.5% 的複合年成長率成長。著名的生物技術和製藥公司的存在、政府對癌症研究的大力支持以及公眾對早期檢測意識的提高，鞏固了美國在這個快速發展的領域的地位。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 癌症盛行率上升
    • 診斷技術不斷進步
    • 增加對癌症研究的投資
    • 提高認知和篩檢計劃
  • 產業陷阱與挑戰
    • 先進診斷技術的高成本
    • 嚴格的法規和漫長的審核流程
• 成長潛力分析
• 未來市場趨勢
• 技術景觀
• 定價分析
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品和服務分類，2021 - 2032 年

• 主要趨勢
• 產品
  • 儀器儀表
  • 套件和消耗品
• 服務

第 6 章：市場估計與預測：按技術分類，2021 - 2032 年

• 主要趨勢
• 新一代定序 (NGS)
• 聚合酶鍊式反應 (PCR)
• DNA微陣列
• 連接複用
• 其他技術

第 7 章：市場估計與預測：按癌症類型，2021 - 2032 年

• 主要趨勢
• 乳癌
• 肺癌
• 大腸直腸癌
• 攝護腺癌
• 子宮頸癌
• 肝癌
• 其他癌症類型

第 8 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 篩檢和早期發現
• 預測和監測
• 治療選擇
• 復發監測
• 其他應用

第 9 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 醫院和診所
• 診斷實驗室
• 學術研究機構
• 其他最終用戶

第 10 章：市場估計與預測：按地區分類，2021 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：公司簡介

• Agilent
• Almac
• Bio-Rad Laboratories
• Exact Sciences
• F. Hoffmann-La Roche
• GenScript
• Guardant Health
• Illumina
• Karkinos Healthcare
• Qiagen
• Koninklijke Philips
• Thermo Fisher Scientific

The Global Next Generation Cancer Diagnostics Market reached USD 15.5 billion in 2023 and is projected to grow at a 10% CAGR from 2024 to 2032. The surge in demand is primarily fueled by the shift towards personalized medicine, which tailors treatments based on individual genetic and molecular data. Advanced diagnostic technologies, including next-generation sequencing (NGS) and liquid biopsy, are central to identifying genetic mutations and specific cancer biomarkers. These capabilities enhance early detection and optimize targeted therapy selection.

Next-generation cancer diagnostics introduce advanced tools and techniques enabling precise, early detection and personalized cancer analysis. These advancements improve disease monitoring and risk assessment, allowing for the refined selection of targeted therapies. By focusing on the unique genetic, molecular, and cellular characteristics of tumors, this market is leading a revolution in cancer care, driven by precision medicine's potential to achieve better clinical outcomes and more effective treatment.

The market is divided into products and services, with the products segment taking a significant share and expected to grow at a 9.8% CAGR over the forecast period. This segment includes instruments and kits & consumables, all essential for diagnostic accuracy and efficiency. Demand is high for advanced sequencing platforms, PCR machines, and imaging devices used widely across hospitals, laboratories, and research institutions, contributing significantly to market revenue.

Technologically, the next generation cancer diagnostics market from the NGS segment held 32.5% share in 2023 due to its ability to provide detailed genomic insights quickly and accurately. NGS's role in identifying genetic mutations and biomarkers is vital for early cancer detection and personalized treatment, with growing cancer prevalence, NGS innovations, and decreasing costs driving adoption.

In the U.S., the next-generation cancer diagnostics market is set to grow at a 9.5% CAGR through 2032. The country leads the market due to its advanced healthcare infrastructure, substantial R&D investments, and emphasis on innovation. The presence of prominent biotechnology and pharmaceutical firms, strong government backing for cancer research, and increased public awareness of early detection reinforces the U.S.'s position in this rapidly evolving field.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cancer
    • 3.2.1.2 Growing advancement in diagnostic technologies
    • 3.2.1.3 Increased investments in cancer research
    • 3.2.1.4 Growing awareness and screening programs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High costs of advanced diagnostics technologies
    • 3.2.2.2 Stringent regulations and lengthy approval processes
• 3.3 Growth potential analysis
• 3.4 Future market trends
• 3.5 Technology landscape
• 3.6 Pricing analysis
• 3.7 Regulatory landscape
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product & Service, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Products
  • 5.2.1 Instruments
  • 5.2.2 Kits & consumables
• 5.3 Services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Next-generation sequencing (NGS)
• 6.3 Polymerase chain reaction (PCR)
• 6.4 DNA microarrays
• 6.5 Multiplexing
• 6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Breast cancer
• 7.3 Lung cancer
• 7.4 Colorectal cancer
• 7.5 Prostate cancer
• 7.6 Cervical cancer
• 7.7 Liver cancer
• 7.8 Other cancer types

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Screening and early detection
• 8.3 Prognostics and monitoring
• 8.4 Therapy selection
• 8.5 Recurrence monitoring
• 8.6 Other applications

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals & clinics
• 9.3 Diagnostic laboratories
• 9.4 Academic & research institutions
• 9.5 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Agilent
• 11.2 Almac
• 11.3 Bio-Rad Laboratories
• 11.4 Exact Sciences
• 11.5 F. Hoffmann-La Roche
• 11.6 GenScript
• 11.7 Guardant Health
• 11.8 Illumina
• 11.9 Karkinos Healthcare
• 11.10 Qiagen
• 11.11 Koninklijke Philips
• 11.12 Thermo Fisher Scientific